Jinfukang clinical trials
How each study uses jinfukang is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2004 (1)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 4
Shanghai University of Traditional Chinese Medicine (2) · Memorial Sloan Kettering Cancer Center (1) · China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (1) · lihegen (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses jinfukang is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Jinfukang Oral Liquid Combined With Chemotherapy for Treating Driver Gene-negative Advanced NSCLCStatus unknownPhase 4China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.NCT05098990Written as Jinfukang oral liquid
- the"Fuzheng" Therapy of TCM to Improve the Survival Quality of Early-stage NSCLC by Intervening the CTCsCompletedPhase 1Shanghai University of Traditional Chinese MedicineNCT02603003Written as JinFuKang
- Curative Study of Chinese Traditional Medicine to Treat Lung CancerStatus unknownPhase 2/3Shanghai University of Traditional Chinese MedicineNCT02777788Written as JinFuKang
- Postoperative NSCLC Treated With Integrated Medicine Base on Circulating Tumor Cell DetectionStatus unknownPhase 3lihegenNCT03269162Written as Jinfukang Koufuye
- Safety and Pharmacokinetics of Jin Fu Kang in Comb w/Docetaxel for Patients w/Non-Small Cell Lung CancerCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT00260026Written as Jin Fu Kang